Resetting the immune system
Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard™, as a therapeutic tool for resetting the body’s immune system in T-cell mediated diseases. Once injected in the body, T-Guard specifically identifies and eliminates adult T cells, with a strong preference for the activated ones (the ‘trouble makers’).
Following a one-week therapy, T-Guard is then swiftly washed out of the body, and the T cel compartment will be rapidly restored with newly formed, normal behaving, T cells. T-Guard is not only very effective in killing activated T cells, but also acts through mechanisms that are associated with minimal side effects (via apoptosis). Moreover, due to T-Guard’s short half-life and narrow specificity (leaving immune bystander cells unharmed), patients are rendered less vulnerable to opportunistic infections as compared to currently available treatment options.
T-Guard™ has been granted Orphan Designation in the EU and the US for the treatment of Graft-versus-Host Disease (GVHD), a frequent and potentially life-threatening complication of a bone marrow or blood stem cell transplantation.
A Patient’s Story
Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard™ as a potentially life-saving treatment option.